🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD

RecruitingNAAges 40 Years - anyAllSunnybrook Health Sciences Centre
NCT06714526 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Stroke is an important cause of death, disability, and memory problems in adults. The build-up of plaque in arteries inside the brain is known as "intracranial atherosclerotic disease" or "ICAD" for short, and can reduce blood flow in the brain. Clopidogrel is a medicine used to prevent strokes because it stops blood from clotting. However, there are some people who do not get as much benefit from Clopidogrel because of differences in their genes; they have a variation in a certain gene and their body is not able to properly process Clopidogrel. Another medication called Ticagrelor can benefit people who have this genetic variation. The study investigators will randomize patients who have had a stroke due to ICAD to receive genetic testing, or standard of care. The standard-of-care group will take Clopidogrel for 90 days. The genetic testing group will complete a genetic test to see if t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 40 years old, male and female. * TIA or ischemic stroke secondary to symptomatic atherosclerotic stenosis of 30- 99% involving the intracranial ICA or MCA or posterior circulation arteries as evidenced by CT or MR angiography. * Index TIA or ischemic stroke event occurred within past 30 days. * Clinical indication for DAPT for at least 3 months. Exclusion Criteria: * Any contraindication to DAPT. * Any contraindication to use of clopidogrel (Plavix) or ticagrelor (Brilinta), such as pregnancy. A pregnancy test will be performed on all women of child-bearing age prior to enrollment in the study. * Indication for chronic anticoagulation based on guideline recommendations or investigator's judgment (e.g., atrial fibrillation, mechanical heart valve, intracardiac clot, dilated cardiomyopathy, ejection fraction \<30%, etc.). * Intracranial arterial occlusion (i.e. 100% stenosis) responsible for the acute brain ischemia. * Intracranial arterial stenosis secondary to causes other than atherosclerosis. * Extracranial carotid disease with a plan for carotid revascularization. * Intraluminal thrombus. * Unstable subdural hematoma within 12 months of randomization not amenable to embolization. * Previous spontaneous hemorrhagic stroke. * Traumatic brain hemorrhage within 1 month of randomization. * Living in a nursing home or requiring daily nursing care or assistance with activities of daily living. * Intracranial tumor (except meningioma) or any intracranial vascular malformation. * Life expectancy less than 6 months. * Enrolment in another study that would conflict with the current study.
💊

What it tests

  • Point-of-Care CYP2C19 Testing
  • ticagrelor + aspirin
  • clopidogrel + aspirin
📍

Where

2 sites
University of Calgary
Calgary, Canada
Dr. Mark I. Boulos - Sunnybrook Health Sciences Centre
Toronto, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy